Preclinical perspectives on the use of platinum compounds in cancer chemotherapy.

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Seminars in Oncology

• Publication date

  2004-12-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1053/J.SEMINONCOL.2004.11.004PMID 15726528
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Molecular profiling predicts clinical outcome in patients with metastatic colorectal cancer treated with 5-FU/oxaliplatin.

  2004cited by this paper
• Antitumor active trans-platinum compounds.

  2004cited by this paper
• Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapy in the A549 non-small-cell lung cancer cell line

  2004cited by this paper
• Development of a high-throughput screen for inhibitors of replication protein A and its role in nucleotide excision repair.

  2004cited by this paper
• Modulation of the cellular pharmacology of cisplatin and its analogs by the copper exporters ATP7A and ATP7B.

  2004cited by this paper
• Modeling the response of colorectal cancer (CRC) to common chemotherapy using multivariate gene expression.

  2004cited by this paper
• Polynuclear platinum drugs.

  2004cited by this paper
• The proteasome inhibitor, bortezomib, in combination with gemcitabine (Gem) and carboplatin (Carbo) in advanced non-small cell lung cancer (NSCLC): Final results of a phase I California Cancer Consortium study.

  2004cited by this paper
• Cytotoxicity, DNA strand breakage and DNA-protein crosslinking by a novel transplatinum compound in human A2780 ovarian and MCF-7 breast carcinoma cells.

  2004cited by this paper
• XPD, XPA, ERCC1 and XPG/ERCC5 single nucleotide polymorphisms (SNPs) in oxaliplatin-treated colorectal cancer (CRC).

  2004cited by this paper
• NMR solution structure of an oxaliplatin 1,2-d(GG) intrastrand cross-link in a DNA dodecamer duplex.

  2004cited by this paper
• Long range 1,4 and 1,6-interstrand cross-links formed by a trinuclear platinum complex. Minor groove preassociation affects kinetics and mechanism of cross-link formation as well as adduct structure.

  2004cited by this paper
• Pharmacogenetic correlates of clinical benefit from gemcitabine and platinum in patients with advanced bladder cancer.

  2004cited by this paper
• Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints.

  2004cited by this paper
• Inhibition of NFκB Increases the Efficacy of Cisplatin in in Vitro and in Vivo Ovarian Cancer Models*

  2004cited by this paper
• ERCC1, RRM1 and XPD mRNA expression as a predictive marker of outcome in non-small-cell lung cancer (NSCLC) patients after platinum/gemcitabine induction chemotherapy followed by surgery.

  2004cited by this paper
• Polymorphisms of DNA repair and glutathione s-transferase genes and progression-free survival (PFS) in treated advanced esophageal cancer (EC) patients

  2004cited by this paper
• Cisplatin: mode of cytotoxic action and molecular basis of resistance

  2003cited by this paper
• Efficiency of extension of mismatched primer termini across from cisplatin and oxaliplatin adducts by human DNA polymerases beta and eta in vitro.

  2003cited by this paper
• DNA binding of the anti-cancer platinum complex trans-[{Pt(NH3)2Cl}2μ-dpzm]2+

  2003cited by this paper
• Suppression of hormone-refractory prostate cancer by a novel nuclear factor kappaB inhibitor in nude mice.

  2003cited by this paper
• RPA phosphorylation in mitosis alters DNA binding and protein-protein interactions.

  2003cited by this paper
• Multi-nuclear platinum complexes as anti-cancer drugs

  2003cited by this paper
• Efficiency of Extension of Mismatched Primer Termini across from Cisplatin and Oxaliplatin Adducts by Human DNA Polymerases β and η in Vitro

  2003cited by this paper
• Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines.

  2003cited by this paper
• Translesion synthesis past platinum DNA adducts by human DNA polymerase mu.

  2003cited by this paper
• Unprecedented monofunctional metalation of adenine nucleobase in guanine- and thymine-containing dinucleotide sequences by a cytotoxic platinum-acridine hybrid agent.

  2003cited by this paper
• Mechanisms controlling sensitivity to platinum complexes: role of p53 and DNA mismatch repair.

  2003cited by this paper
• Xeroderma Pigmentosum Complementation Group A Protein (XPA) Modulates RPA-DNA Interactions via Enhanced Complex Stability and Inhibition of Strand Separation Activity*

  2002cited by this paper
• A phase II trial of ZD0473 in platinum-pretreated ovarian cancer.

  2002cited by this paper
• Metallochaperones: bind and deliver.

  2002cited by this paper
• Strand-specific binding of RPA and XPA to damaged duplex DNA.

  2002cited by this paper
• Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals

  2002cited by this paper
• Cross-linking of a DNA conjugate tethering a cis-bifunctional platinated complex to a target DNA duplex.

  2002cited by this paper
• Recognition of cisplatin adducts by cellular proteins.

  2001cited by this paper
• Stopped-flow Kinetic Analysis of Replication Protein A-binding DNA

  2001cited by this paper
• Mechanisms of resistance to cisplatin.

  2001cited by this paper
• Phase II clinical study of BBR 3464, a novel, bifunctional platinum analogue, in patients with advanced ovarian cancer

  2001cited by this paper
• Cisplatin: from DNA damage to cancer chemotherapy.

  2001cited by this paper
• The novel trinuclear platinum complex BBR3464 induces a cellular response different from cisplatin.

  2001cited by this paper
• 2.4 A crystal structure of an oxaliplatin 1,2-d(GpG) intrastrand cross-link in a DNA dodecamer duplex.

  2001cited by this paper
• An update on satraplatin: the first orally available platinum anticancer drug

  2000cited by this paper
• BBR 3464: a novel triplatinum complex, exhibiting a preclinical profile of antitumor efficacy different from cisplatin.

  2000cited by this paper
• Platinum-Based Drugs in Cancer Therapy

  2000cited by this paper
• Copper-transporting P-type adenosine triphosphatase (ATP7B) is associated with cisplatin resistance.

  2000cited by this paper
• The Chemistry of Cisplatin in Aqueous Solution

  2000cited by this paper
• Polynuclear Charged Platinum Compounds as a New Class of Anticancer Agents

  2000cited by this paper
• Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells: role of ERCC1-XPF.

  2000cited by this paper
• Chemistry and Structural Biology of 1,2-Interstrand Adducts of Cisplatin

  2000cited by this paper
• Overexpression and purification of human XPA using a baculovirus expression system.

  2000cited by this paper
• A 1H NMR study of the oligonucleotide binding of [(en)Pt(mu-dpzm)2Pt(en)]Cl4.

  2000cited by this paper
• Polynuclear Charged Platinum Compounds as a New Class of Anticancer Agents: Toward a New Paradigm

  2000cited by this paper
• Debating Democracy Assistance: Toward a New Paradigm

  1999cited by this paper
• SELECTIVE RECOGNITION OF A DC-DG BASE PAIR BY OLIGONUCLEOTIDE-DIRECTED TRIPLEX FORMATION USING A DC RESIDUE TETHERING AN INTERCALATOR

  1999cited by this paper
• NMR solution structure of a DNA dodecamer duplex containing a cis-diammineplatinum(II) d(GpG) intrastrand cross-link, the major adduct of the anticancer drug cisplatin.

  1998cited by this paper
• Oxaliplatin: a review of preclinical and clinical studies.

  1998cited by this paper
• DNA TRIPLEX STABILIZATION USING A TETHERED MINOR GROOVE BINDING HOECHST 33258 ANALOGUE

  1997cited by this paper
• DNA modifications by antitumor trans-[PtCl2(E-iminoether)2].

  1997cited by this paper
• cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.

  1997cited by this paper
• DNA adducts of antitumor trans-[PtCl2 (E-imino ether)2].

  1996cited by this paper
• JANUS WEDGES: a new approach towards nucleobase-pair recognition

  1996cited by this paper
• Activation of the trans geometry in platinum antitumor complexes: a survey of the cytotoxicity of trans complexes containing planar ligands in murine L1210 and human tumor panels and studies on their mechanism of action.

  1991cited by this paper
• Overexpression of metallothionein confers resistance to anticancer drugs.

  1988cited by this paper
• Sequence-specific recognition of the major groove of DNA by oligodeoxynucleotides via triple helix formation. Footprinting studies.

  1988cited by this paper
• Site-specific oligonucleotide binding represses transcription of the human c-myc gene in vitro.

  1988cited by this paper
• Sequence-specific cleavage of double helical DNA by triple helix formation.

  1987cited by this paper
• Cancer : Principles and Practice of Oncology

  1982cited by this paper

• Will the Interactions of Some Platinum (II)-Based Drugs with B-Vitamins Reduce Their Therapeutic Effect in Cancer Patients? Comparison of Chemotherapeutic Agents such as Cisplatin, Carboplatin and Oxaliplatin—A Review

  2023cites this paper
• Surface-Functionalized Terahertz Metamaterial Biosensor Used for the Detection of Exosomes in Patients.

  2022cites this paper
• Affinities to Oxaliplatin: Vitamins from B Group vs. Nucleobases

  2022cites this paper
• THUMP domain containing 2 protein possibly induces resistance to cisplatin and 5‐fluorouracil in in vitro human esophageal squamous cell carcinoma cells as revealed by transposon activation mutagenesis

  2019cites this paper
• Current Status for Oral Platinum (IV) Anticancer Drug Development

  2018cites this paper
• Selective Ru(II)/lawsone complexes inhibiting tumor cell growth by apoptosis.

  2017cites this paper
• The 5′UTR variant of ERCC5 fails to influence outcomes in ovarian and lung cancer patients undergoing treatment with platinum-based drugs

  2016cites this paper
• Dermal Drug Delivery for Cutaneous Malignancies: Literature at a Glance

  2016cites this paper
• Metal complex interactions with DNA.

  2015cites this paper
• Effect of chirality in platinum drugs

  2015cites this paper
• Platinum Complexes and Zinc Finger Proteins: From Target Recognition to Fixation

  2014cites this paper
• Evaluation of Platinum Chemotherapy in Combination with HER2-Targeted α-Particle Radiation

  2013cites this paper
• Synthesis, characterization and antitumor activity of new ferrocene incorporated N,N'-disubstituted thioureas.

  2012cites this paper
• A Tetrazolato‐Bridged Dinuclear Platinum(II) Complex Exhibits Markedly High in vivo Antitumor Activity against Pancreatic Cancer

  2011cites this paper
• Solvent effects and dynamic averaging of 195Pt NMR shielding in cisplatin derivatives.

  2011cites this paper
• Transition metal based anticancer drugs.

  2011cites this paper
• Medicinal inorganic chemistry : state of the art, new trends, and a vision of the future

  2011cites this paper
• The Challenge of Establishing Reliable Screening Tests for Selecting Anticancer Metal Compounds

  2011cites this paper
• The Synthesis of Platinum(II) Intercalators

  2011cites this paper
• Methods to evaluate transporter activity in cancer.

  2010cites this paper
• Characteristic effect of an anticancer dinuclear platinum(II) complex on the higher-order structure of DNA

  2010cites this paper
• In Vitro Evaluation of Oxoplatin: An Oral Platinum(IV) Anticancer Agent

  2009cites this paper
• Metals in Medicine

  2009cites this paper
• Oxaliplatin: pre-clinical perspectives on the mechanisms of action, response and resistance

  2009cites this paper
• Differences in the cellular response and signaling pathways of cisplatin and BBR3464 ([[trans-PtCl(NH3)(2)]2mu-(trans-Pt(NH3)(2)(H2N(CH2)(6)-NH2)2)]4+) influenced by copper homeostasis.

  2007cites this paper
• The polyamines spermidine and spermine retard the platination rate of single-stranded DNA oligomers and plasmids.

  2007cites this paper
• Insights into the mechanism of action of platinum anticancer drugs from multinuclear NMR spectroscopy

  2006cites this paper
• Clinical application of oxaliplatin in epithelial ovarian cancer

  2006cites this paper
• Novel transplatinum(II) complexes with [N2O2] donor sets. Cellular pharmacology and apoptosis induction in Pam 212-ras cells.

  2006cites this paper
• More pronounced salt dependence and higher reactivity for platination of the hairpin r(CGCGUUGUUCGCG) compared with d(CGCGTTGTTCGCG)

  2006cites this paper
• Commentary (Muggia/Blank): Modern Management of Recurrent Ovarian Carcinoma

  2005cites this paper
• Synthesis, characterization, and cytotoxicity of a novel highly charged trinuclear platinum compound. Enhancement of cellular uptake with charge.

  2005cites this paper